Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic
Yükleniyor...
Dosyalar
Tarih
2021
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Turkiye Klinikleri
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Background/aim: To evaluate treatment adherence and predictors of drug discontinuation among patients with inflammatory arthritis receiving bDMARDs within the first 100 days after the announcement of the COVID-19 pandemic. Materials and methods: A total of 1871 patients recorded in TReasure registry for whom advanced therapy was prescribed for rheumatoid arthritis (RA) or spondyloarthritis (SpA) within the 3 months (6–9 months for rituximab) before the declaration of COVID-19 pandemic were evaluated, and 1394 (74.5%) responded to the phone survey. Patients’ data regarding demographic, clinical characteristics and disease activity before the pandemic were recorded. The patients were inquired about the diagnosis of COVID-19, the rate of continuation on bDMARDs, the reasons for treatment discontinuation, if any, and the current general disease activity (visual analog scale, [VAS]). Results: A total of 1394 patients (493 RA [47.3% on anti-TNF] patients and 901 SpA [90.0% on anti-TNF] patients) were included in the study. Overall, 2.8% of the patients had symptoms suggesting COVID-19, and 2 (0.15%) patients had PCR-confirmed COVID-19. Overall, 18.1% of all patients (13.8% of the RA and 20.5% of the SpA; p = 0.003) discontinued their bDMARDs. In the SpA group, the patients who discontinued bDMARDs were younger (40 [21–73] vs. 44 years [20–79]; p = 0.005) and had higher general disease activity; however, no difference was relevant for RA patients. Conclusion: Although the COVID-19 was quite uncommon in the first 100 days of the pandemic, nearly one-fifth of the patients discontinued bDMARDs within this period. The long-term effects of the pandemic should be monitored. © TÜBİTAK.
Açıklama
Anahtar Kelimeler
Biologic DMARDs, COVID-19, Rheumatoid arthritis, Spondyloarthritis, abatacept, adalimumab, certolizumab pegol, disease modifying antirheumatic drug, etanercept, golimumab, hydroxychloroquine, infliximab, leflunomide, methotrexate, rituximab, salazosulfapyridine, secukinumab, tocilizumab, antirheumatic agent, adult, aged, Ankylosing Spondylitis Disease Activity Score, Article, Bath ankylosing spondylitis disease activity index, Bath ankylosing spondylitis functional index, cohort analysis, coronavirus disease 2019, Crohn Disease Activity Index, DAS28, disease activity, drug withdrawal, erythrocyte sedimentation rate, female, Health Assessment Questionnaire, health status, human, major clinical study, male, observational study, pandemic, polymerase chain reaction, prospective study, questionnaire, remission, rheumatoid arthritis, Simplified Disease Activity Index, spondylarthritis, visual analog scale, adolescent, medication compliance, middle aged, pandemic, register, rheumatoid arthritis, very elderly, young adult, Adolescent, Adult, Aged, Aged, 80 and over, Antirheumatic Agents, Arthritis, Rheumatoid, Cohort Studies, COVID-19, Female, Humans, Male, Medication Adherence, Middle Aged, Pandemics, Prospective Studies, Registries, SARS-CoV-2, Young Adult
Kaynak
Turkish Journal of Medical Sciences
WoS Q Değeri
Q3
Scopus Q Değeri
Q3
Cilt
51
Sayı
4
